MedImmune's neo stimulus package
MedImmune is using its IO arsenal to back up its neoantigen vaccines
The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the personalized vaccines will require cocktails of boosting agents and backing by pharmas with deep immuno-oncology benches to succeed.
Last month, MedImmune launched its neoantigen cancer vaccine collaboration with Washington University in St. Louis. David Berman, MedImmune’s SVP and Head of Oncology Innovative Medicines, told BioCentury the company partnered with WashU because of the university’s pioneering preclinical and clinical work in the neoantigen space...
BCIQ Company Profiles
BCIQ Target Profiles
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)
Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18)
Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Tumor necrosis factor (TNF) receptor superfamily member 4 (OX40) (TNFRSF4) (CD134)